## Epidemiology of P. vivax Malaria **Key Point:** P. vivax is the most common cause of malaria in India and has a unique relapse pattern due to hypnozoites (dormant liver forms) that can reactivate months to years after the primary attack. ### Clinical Presentation - **Fever pattern:** Tertian (every 48 hours) — fever on days 1, 3, 5, etc. - **Periodicity:** Synchronized rupture of infected RBCs occurs every 48 hours - **Typical cycle:** Fever, chills, sweating lasting 8–10 hours, followed by defervescence ### Pathophysiology of Relapse 1. **Hypnozoites** are dormant forms in hepatocytes that escape the initial attack of antimalarials 2. **Reactivation** can occur weeks to months (even years) after the primary infection 3. **Trigger factors:** Immunosuppression, stress, or concurrent illness may precipitate relapse 4. **Prevention:** Primaquine (8-aminoquinoline) is required to eliminate hypnozoites and prevent relapse ### Epidemiological Significance in India | Feature | P. vivax | P. falciparum | |---------|----------|---------------| | Fever pattern | Tertian (48 hrs) | Quotidian or irregular | | Hypnozoites | Present (relapse common) | Absent (no relapse) | | Severity | Milder | Severe, cerebral malaria | | Geographic distribution | Pan-India, especially plains | Forest/tribal areas | | Relapse risk | 20–40% without primaquine | None | **Clinical Pearl:** In endemic areas like Jharkhand, P. vivax accounts for ~60% of malaria cases. The relapse pattern makes it epidemiologically significant for sustained transmission — each relapse can serve as a reservoir for mosquito infection. **High-Yield:** Primaquine is mandatory for P. vivax (and P. ovale) to prevent relapse. G6PD deficiency screening is essential before primaquine administration in endemic populations [cite:Park 26e Ch 10]. ### Why Relapse Occurs - Hypnozoites are sequestered in the liver and are not exposed to blood-stage antimalarials (chloroquine, artemisinin derivatives) - Only 8-aminoquinolines (primaquine, tafenoquine) are effective against hypnozoites - Without primaquine, the patient is at risk of clinical relapse 2–12 months later
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.